BNP Paribas Financial Markets Portfolio holdings
BNP Paribas Financial Markets, a core component of BNP Paribas’s Corporate & Institutional Banking (CIB) division, is a global leader in trading and market-making, headquartered in Paris with major hubs in London, New York, Hong Kong, and Singapore. Specializing in derivatives across all asset classes—equities, fixed income, commodities, and foreign exchange—it provides innovative investment, hedging, and financing solutions to corporate clients, institutional investors, and financial institutions worldwide. Known for its advanced technological infrastructure and quantitative expertise, the division excels in structured financing and electronic trading, supported by a robust balance sheet and a diversified business model that proved resilient during the 2008 financial crisis. With a presence in over 50 countries and a client base exceeding 13,000, BNP Paribas Financial Markets drives market liquidity and offers cutting-edge research and execution services, reinforcing its position as a top-tier player in global capital markets.
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
+$1.69B |
| 2 |
Apple
AAPL
|
+$892M |
| 3 |
SPDR S&P Biotech ETF
XBI
|
+$799M |
| 4 |
Industrial Select Sector SPDR Fund
XLI
|
+$793M |
| 5 |
GE Aerospace
GE
|
+$748M |
Top Sells
| 1 |
Tesla
TSLA
|
+$362M |
| 2 |
Utilities Select Sector SPDR Fund
XLU
|
+$345M |
| 3 |
NVIDIA
NVDA
|
+$258M |
| 4 |
MetLife
MET
|
+$257M |
| 5 |
Meta Platforms (Facebook)
META
|
+$223M |
Sector Composition
| 1 | Technology | 26.74% |
| 2 | Consumer Discretionary | 11.23% |
| 3 | Financials | 10.63% |
| 4 | Healthcare | 8.41% |
| 5 | Communication Services | 8.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3826
Century Therapeutics
IPSC
$44.8M
| $9.89K | ﹤0.01% |
+9,792
| New | +$9.89K |
|
3827
Tenaya Therapeutics
TNYA
$209M
| $9.79K | ﹤0.01% |
+6,849
| New | +$9.79K |
|
|
AKYA
3828
DELISTED
Akoya BioSciences
AKYA
| $9.76K | ﹤0.01% |
+4,263
| New | +$9.76K |
|
3829
Ispire Technology
ISPR
$186M
| $9.65K | ﹤0.01% |
+1,918
| New | +$9.65K |
|
3830
Shattuck Labs
STTK
$94.8M
| $9.61K | ﹤0.01% |
+7,939
| New | +$9.61K |
|
3831
Lineage Cell Therapeutics
LCTX
$295M
| $9.6K | ﹤0.01% |
+19,099
| New | +$9.6K |
|
|
BCYC
3832
Bicycle Therapeutics
BCYC
$487M
| $9.52K | ﹤0.01% |
680
-118
| -15% | -$1.65K |
|
3833
Global X 1-3 Month T-Bill ETF
CLIP
$1.52B
| $9.51K | ﹤0.01% |
95
+1
| +1% | +$100 |
|
3834
Ramaco Resources Class B
METCB
$999M
| $9.32K | ﹤0.01% |
+943
| New | +$9.32K |
|
|
PARAA
3835
DELISTED
Paramount Global Class A
PARAA
| $9.3K | ﹤0.01% |
+417
| New | +$9.3K |
|
3836
Pyxis Oncology
PYXS
$115M
| $9.22K | ﹤0.01% |
+5,910
| New | +$9.22K |
|
|
ADAG
3837
Adagene
ADAG
$110M
| $9.17K | ﹤0.01% |
+4,700
| New | +$9.17K |
|
|
ORKA
3838
Oruka Therapeutics, Inc. Common Stock
ORKA
$605M
| $9.08K | ﹤0.01% |
+468
| New | +$9.08K |
|
3839
Metagenomi
MGX
$70.9M
| $9.04K | ﹤0.01% |
2,504
-10,295
| -80% | -$37.2K |
|
3840
PepGen
PEPG
$44.3M
| $9.04K | ﹤0.01% |
+2,384
| New | +$9.04K |
|
3841
HilleVax
HLVX
$105M
| $9.03K | ﹤0.01% |
+4,363
| New | +$9.03K |
|
3842
WisdomTree Bloomberg US Dollar Bullish Fund
USDU
$151M
| $9.02K | ﹤0.01% |
326
+324
| +16,200% | +$8.96K |
|
3843
Sagimet Biosciences
SGMT
$229M
| $8.9K | ﹤0.01% |
+1,977
| New | +$8.9K |
|
3844
The ONE Group
STKS
$82.7M
| $8.87K | ﹤0.01% |
3,058
-7,297
| -70% | -$21.2K |
|
3845
Black Diamond Therapeutics
BDTX
$192M
| $8.8K | ﹤0.01% |
+4,113
| New | +$8.8K |
|
3846
a.k.a. Brands
AKA
$114M
| $8.78K | ﹤0.01% |
469
-34
| -7% | -$637 |
|
3847
Global X NASDAQ-100 Covered Call ETF
QYLD
$8.28B
| $8.67K | ﹤0.01% |
476
-3,830
| -89% | -$69.8K |
|
3848
First United
FUNC
$239M
| $8.63K | ﹤0.01% |
+256
| New | +$8.63K |
|
3849
Scilex Holding
SCLX
$176M
| $8.62K | ﹤0.01% |
+577
| New | +$8.62K |
|
3850
Solarmax Technology
SMXT
$60.8M
| $8.58K | ﹤0.01% |
5,294
-29,477
| -85% | -$47.8K |
|